Immunocompromised haematological patients are at high risk for severe, often fatal, respiratory syncytial virus (RSV) pneumonia. In the 2001 winter season, 16 of 195 (8.2%) adult haematological in-patients were diagnosed with RSV infection. Eight patients had undergone stem cell transplantation. The median age was 53 years (range 20-67). A total of 11 patients had nosocomial RSV infection while the rest (five) had community-acquired infection. All patients were febrile and had upper respiratory tract infection (URTI). Eight patients (50%) developed lower RTI. Two of the 16 patients (12.5%) died of respiratory failure, due to the RSV pneumonia, despite ICU admission and supportive ventilation. None of the studied patients received ribavirin therapy or specific RSV immunoglobulin. Two patients autografted for multiple myeloma (MM) showed delayed neutrophil and platelet engraftment despite receiving an adequate dose of stem cells. A third patient undergoing a CD34+ selected HLAmatched sibling mini-allograft for relapsed MM showed graft failure shortly after RSV infection. In our series, RSV infection was concurrent with an outbreak in the community. Unlike other published series, no specific antiviral treatment for RSV pneumonia was used and yet the overall outcome in our patients was favourable. Furthermore, RSV infection in the pre-engraftment period after autologous transplantation was associated with delayed engraftment.
Immunocompromised haematological patients are at high risk for severe, often fatal, respiratory syncytial virus (RSV) pneumonia. In the 2001 winter season, 16 of 195 (8.2%) adult haematological in-patients were diagnosed with RSV infection. Eight patients had undergone stem cell transplantation. The median age was 53 years (range 20-67). A total of 11 patients had nosocomial RSV infection while the rest (five) had community-acquired infection. All patients were febrile and had upper respiratory tract infection (URTI). Eight patients (50%) developed lower RTI. Two of the 16 patients (12.5%) died of respiratory failure, due to the RSV pneumonia, despite ICU admission and supportive ventilation. None of the studied patients received ribavirin therapy or specific RSV immunoglobulin. Two patients autografted for multiple myeloma (MM) showed delayed neutrophil and platelet engraftment despite receiving an adequate dose of stem cells. A third patient undergoing a CD34+ selected HLAmatched sibling mini-allograft for relapsed MM showed graft failure shortly after RSV infection. In our series, RSV infection was concurrent with an outbreak in the community. Unlike other published series, no specific antiviral treatment for RSV pneumonia was used and yet the overall outcome in our patients was favourable. Furthermore, RSV infection in the pre-engraftment period after autologous transplantation was associated with delayed engraftment. Bone Marrow Transplantation (2003) 32, [195] [196] [197] [198] [199] [200] [201] [202] [203] . doi:10.1038/sj.bmt.1704116 Keywords: respiratory syncytial virus; stem cell transplantation; engraftment; immunocompromised; RSV pneumonia Respiratory syncytial virus (RSV) is the most common viral agent causing both upper and lower respiratory tract infections in children and adults. 1 The yearly incidence of RSV infection in hospitalised patients ranges between 2 and 12% and depends upon the severity of outbreaks in the community at the time. 2 RSV is a common cause of lower respiratory tract illness in immunocompromised patients. [3] [4] [5] Up to 70% of stem cell or bone marrow transplant (BMT) recipients who experience RSV infection in the pre-engraftment period will develop pneumonia. 6, 7 Once pneumonia develops, the overall mortality has been reported to be as high as 60-80%. 3, 6, [8] [9] Those patients with RSV pneumonia who develop respiratory failure requiring mechanical ventilation almost invariably die from the infection. Treatment options for established RSV pneumonia are limited and treatment is often unsuccessful. 4, 10, 11 RSV infection in hospitalised patients usually occurs in the setting of community outbreaks and may be community-or nosocomially acquired. Transmission of RSV takes place by droplet infection or via direct contact with infected persons. The virus can survive on nonporous surfaces, skin and gloves for many hours. RSV is not stable in fine particle aerosols, and hence small-particle air transmission is not considered to be a major route of spread. 1, 2 In this report, we describe the outcome of 16 adult haematological in-patients, including eight stem cell transplant recipients, who acquired RSV infection either in the community (5) or nosocomially (11) . The infections occurred concurrently with an epidemic in the community. The incidence of RSV pneumonia, the outcome without specific therapy, infection control consequences and the effect of RSV on the engraftment in the transplanted preengrafted patients (3) are described.
Methods
The Haematology Department at the Royal Adelaide Hospital (RAH) is a tertiary referral centre for haematological malignancies and includes a bone marrow transplantation unit where autologous and allogeneic marrow and peripheral blood stem cell transplants (PBSCT) are performed. The transplant recipients are cared for in single high-energy particulate air (HEPA)-filtered rooms from the time of conditioning until postengraftment. Other immunocompromised haematological patients are accommodated either in HEPA-filtered single rooms or four-bed bays. All individuals entering any patient room are required to wash their hands.
The index case of respiratory syncytial virus infection occurred in a 20-year-old male patient with relapsed acute lymphoblastic leukaemia (ALL), who was severely immunosuppressed after receiving reinduction chemotherapy (FLAG-Ida). After two other cases were identified in the same ward, all febrile in-patients and all in-patients who complained of upper respiratory tract symptoms were screened for RSV disease. Nasopharyngeal aspirates (NPA), sputum samples and in one case bronchoalveolar lavage (BAL) fluid were obtained as respiratory tract specimens.
The presence of RSV was demonstrated by enzyme immunoassay (14 patients) of the neat specimens (sputum, NPA, BAL) and by culture of the specimens in MDCK and LLC-MK2 cell lines and repeat enzyme immunoassay on cultured cells. 12, 13 In two patients, serological evidence of RSV was shown by complement fixation tests. Radiological examinations with chest radiograph (CXR) and computed tomogram (CT) scan of the chest were performed when indicated. No patient received specific antiviral therapy, but supportive treatment with granulocyte colony-stimulating factor (G-CSF) to neutropenic patients, oxygen therapy and noninvasive ventilatory support was given as dictated by the patients' clinical state.
The South Australian Department of Human Services provided epidemiological evidence about a community outbreak of RSV, which occurred concurrently ( Figure 1 ).
An acute upper respiratory tract infection (URTI) was defined as the recent onset of rhinorrhoea, nasal or sinus congestion, otitis media, pharyngitis and/or cough with clear chest radiograph. Tracheobronchitis was defined as the presence of a deep, persistent cough in association with rhonchi or coarse rales on chest exam and a clear chest radiograph. Pneumonia was defined as an acute respiratory illness occurring in association with signs and/or symptoms of lower respiratory tract infection (LRTI) and a new radiographic infiltrate. Engraftment was defined as the recovery of neutropenia after transplantation with absolute neutrophil count (ANC)4500/ml. Mild neutropenia was defined as ANCo1500/ml, moderate neutropenia as ANCo1000/ml and severe neutropenia as ANCo500/ml. An infection was defined as nosocomial if symptoms developed 47 days after hospital admission. Figure 1 Total respiratory virus infections in the community (squares), including influenza A and B viruses, parainfluenza 1, 2 and 3 viruses, rhinovirus, over the age of 60 years. The male-to-female ratio was 13:3. Eight patients underwent stem cell transplantation (five sibling HLA-matched allogeneic and three autologous). Of these, five were in the postengraftment period, and three in the preengraftment period when the infection was diagnosed ( Table 1 ). The median interval between transplant and RSV infection for the postengraftment patients was 13 months (range [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] .
Results

The
All of the patients were immunocompromised and 10 patients were neutropenic (six severe, two moderate, two mild) at the time of diagnosis. Underlying illnesses included acute leukaemia (five patients), CML (four), multiple myeloma (three), non-Hodgkin's lymphoma (NHL) (two) and aplastic anaemia and idiopathic thrombocytopaenic purpura (one each). Three patients were receiving high-dose chemotherapy, eight patients were receiving standard-dose chemotherapy or radiotherapy, one patient was receiving prednisolone and four were receiving immunosuppressive therapy for graft-versus-host disease postengraftment after HLA-matched sibling allogeneic peripheral blood stem cell transplantation (PBSCT).
Three patients acquired RSV infection in the immediate post-transplant period, prior to engraftment (Table 2) . No other viruses or bacteria could be identified in these three patients at the time of RSV infection. These patients had multiple myeloma and developed RSV infection within 9 days of stem cell transplantation (two autologous and one allogeneic); all showed delayed engraftment. The two autografted patients (case no. 8, 12) had been treated with chemotherapy prior to the transplantation (three cycles of VAD followed by high-dose cyclophosphamide 5 g/m /kg BW (harvested at the same time as those used in the first ABSCT). In the pre-engraftment period, this patient developed febrile neutropenia with radiological findings (X-ray, CT chest) of early pneumonia, but no respiratory viruses or bacteria could be isolated. Bronchoscopy was not performed as she responded quickly to broad-spectrum antibiotics. She did not receive G-CSF. Of note, the engraftment kinetics were strikingly different between the two transplants, with haematopoietic recovery occurring significantly earlier after the second transplant without RSV infection ( Table 3) .
The allografted patient (case no. 2) was a 50-year-old female who had undergone an HLA-matched sibling T-cell depleted mini-allogeneic PBSCT for relapsed multiple myeloma 2 years after autografting. The conditioning regimen consisted of fludarabine and melphalan. The transplanted donor cells were CD34+ selected using the Isolex System. The dose of selected CD34+ cells was 6.54 Â 10 6 /kg. This patient showed early signs of engraftment on day 13 post-transplantation with a white cell count (WCC) of 500/ml and a neutrophil count of 400/ml. Interestingly, both counts declined very rapidly on day 14, which was 5 days after the onset of RSV infection ( Figure 2) . A bone marrow biopsy done at day 29 post allografting showed an empty marrow in both the bone marrow smear and trephine without any evidence of engraftment. She remained pancytopenic and died 64 days post transplantation following a massive cerebral haemorrhage.
Clinical presentation
All of the patients were febrile and had symptoms of URTI. Of these, 13 patients had rhinitis (rhinorrhoea, nasal congestion), 13 had cough and 11 patients were hypoxic and required supplemental oxygen therapy (Table 4) . Three of these patients (case no. 1, 10, 11) were admitted to the Intensive Care Unit (ICU), where two of them received continuous positive airway pressure (CPAP) respiratory support. Despite this, two of these patients (case no. 10, 11) died from respiratory failure. One patient returned from the ICU (the index case, no. 1) and recovered from RSV pneumonia. Five of 16 patients had concurrent other infections at the time RSV infection was diagnosed. Two patients had proven or suspected fungal disease: one had Aspergillus fumigatus in BAL (case no. 15) and one had possible aspergillus sinusitis (based on ENT-endoscopy) (case no. 7). Two patients had bacterial infections: one patient with ALL and pneumonic infiltrates on CXR had a bacteraemia with Streptococcus viridans (the index case, no. 1) and one had a central venous line infection with Staphylococcus epidermidis and Agrobacterium species (case no. 4). One patient was undergoing treatment for cutaneous varicella zoster virus infection at the time RSV was diagnosed (case no. 5).
Radiological findings
All patients underwent chest radiography (CXR). These were normal in 11 patients. The remaining five patients had alveolar opacities, which were extensive and bilateral in four cases, consistent with viral pneumonia. A total of 12 patients underwent CT scan of the chest. Three patients Table 4 . Respiratory syncytial virus infection A Abdallah et al with normal CXR had changes consistent with bronchopneumonia demonstrated on CT scan. All patients with abnormal CXR had these findings confirmed by CT scan; however in two cases the pathology demonstrated by CT scan suggested another concurrent pathogen, such as fungal infection. Three patients had CT scans of facial sinuses performed and significant sinusitis was shown on all three examinations. One patient probably had concurrent aspergillus sinusitis, but in the other two cases no other pathogens were detected.
Treatment
None of the patients received specific antiviral therapy with ribavirin or RSV-specific immune globulin. At the Royal Adelaide Hospital (RAH), Occupational Health and Safety considerations restrict aerosolised ribavirin to patients who are on closed circuit ventilators and none of our patients progressed to this level of support. The use of RSV immunoglobulin, oral and intravenous ribavirin for RSV pneumonia is controversial. 4, 5, 14 All neutropenic patients, except those in the pre-engraftment phase post-PBSCT, received supportive treatment with G-CSF. Eight patients with RSV pneumonia received oxygen therapy; three required noninvasive, positive pressure ventilation. Two patients (case no. 1, 11) received intravenous polyclonal gammaglobulin after they developed severe respiratory failure due to RSV pneumonia. One of these patients died, the other survived.
Overall outcome
Eight patients (50%) had pneumonia, and the remaining eight had upper respiratory tract involvement only. None of the patients with URTI only died from RSV infection. RSV infection was the presumed cause of death in two of the eight patients who developed pneumonia. A 57-year-old male patient (case no. 10) who had undergone autologous PBSCT for NHL 12 months before presented with respiratory failure and died within 48 h of presentation. He had high titres of anti-RSV antibodies in his blood but no virus could be detected in sputum samples. No other pathogens were found. A second male patient (case no. 11), also more than 12 months after HLA-matched sibling allogeneic transplantation for AML, developed nosocomially acquired RSV pneumonia resulting in death from respiratory failure. All other patients recovered from RSV infection.
Infection control
RSV infection was diagnosed between 0 and 30 days (median 9) postadmission. In 11 of 16 patients, the infection was defined as acquired in hospital. All but one of the patients were housed in the Haematology wards at the time the diagnosis of RSV infection was made, five in four-bed bays, eight in single HEPA-filtered rooms. Three patients were outlied in nearby wards but were attended daily by the same medical staff. At the time of the outbreak, there was a high prevalence of RSV infection in the community and there were reports of staff illness with upper respiratory tract symptoms, although no staff member was diagnosed specifically with RSV infection.
The infection control interventions instituted included placement of a patient within a single room once diagnosed, reinforcement of handwashing prior to leaving the patient's room, and barrier protection including gowns, gloves and masks. Eye goggles were not worn. Nursing care was cohorted, with nurses caring for RSV-infected patients not caring for other neutropenic patients on that shift. Inpatients who developed URTI symptoms were screened for the presence of RSV disease with nasopharyngeal aspirates for viral studies. These patients were isolated while awaiting the laboratory results. Patients were taught to sneeze or cough directly into a tissue and dispose of this immediately, with handwashing thereafter. After discharge, the patient rooms were thoroughly cleaned. Staff and visitors with URTI symptoms were excluded from direct patient care or visiting in-patients. Staff from the Infection Prevention and Control Unit provided written and verbal education about RSV to the ward staff and developed a protocol for the inpatient management of RSV infection in liaison with the Haematology ward staff.
Epidemiology
The outbreak occurred during a wet winter season when RSV was common in the general community. During the period from June to September 2001, the Institute of Medical and Veterinary Science (IMVS) laboratory diagnosed 350 RSV infections in respiratory specimens (Figure 1) . A total of 28 of these specimens came from the RAH and 16 of the hospital specimens were from the Haematology Department. There are two major groups of RSV strains (A and B), which can be further subgrouped. Group A and B viruses often circulate simultaneously within geographically confined epidemics, with group A being the most prevalent.
2 Some studies have found that more severe disease in children is associated with group A viruses. 2 Many other studies on the virulence of RSV groups revealed no differences in clinical severity. 15 To date, there is no established correlation between the severity of RSV disease and the RSV strains among immunocompromised adult patients. 2, 15 Eight patients in the present study had positive viral cultures, and five of these took 7 or more days to grow. This may indicate a predominance of type B strains, which are known to grow more slowly in culture; 2 however, formal typing was not performed by us.
Discussion
We describe a prolonged outbreak of RSV infection in adult haematologic immunocompromised inpatients (16 of 195 patients, 8 .2%) during the winter of 2001. Introduction of the virus from the community (31.3%) and nosocomial transmission (68.7%) were probably important in maintaining the outbreak as there was no direct contact between infected patients and uninfected patients after the diagnosis had been made. The hospital outbreak did not end until the community outbreak was waning.
Significant morbidity and 12.5% overall mortality from RSV infection occurred. All patients were febrile and had signs of URTI. A total of 50% of the patients (eight of 16) developed lower respiratory tract compromise with dyspnoea and hypoxia necessitating oxygen therapy. This is similar to rates reported in the literature. 3, 4, 11 Three patients (18.7%) required ventilatory support and two of these died from respiratory failure due to RSV pneumonia. Thus, the mortality in the subset of patients who developed pneumonia was 25%. None of the patients received specific therapy with ribavirin or RSV-specific immunoglobulin. However, two patients who required ICU admission received intravenous polyclonal gammaglobulin, one recovered and the other died. It is difficult to judge whether this has had a beneficial effect in these patients, because the one who recovered showed neutrophil recovery at the same time.
In our cohort, 11 infections were nosocomially acquired and the nosocomial and community outbreaks were closely linked. Previous studies have demonstrated that there are multiple strains of RSV circulating in a given outbreak, suggesting multiple transmission episodes from different sources. 16 We believe that this was the case in this outbreak, as the infected patients did not have direct contact with each other. Despite stringent infection control precautions, new nosocomial cases continued to occur until the community outbreak began to wane. Prevention of nosocomial RSV infection is challenging and requires a multifaceted approach involving strict attention to handwashing, barrier precautions and continuing education of staff, patients and visitors. [17] [18] [19] Bone marrow or stem cell transplant recipients appear to be at higher risk of severe RSV disease. Factors associated with more severe disease include the degree of immunosuppression of the patient, particularly the preengraftment phase in bone marrow or stem cell transplant recipients. In our study we had eight patients who underwent stem cell transplantation. Of these, three received autologous and five allogeneic transplants. Three patients were in the pre-engraftment period (two autologous and one allogeneic).
RSV pneumonia in BMT patients treated with aerosolised ribavirin alone has been associated with 50-70% mortality, 3, 20 while a combination therapy with high-titred RSV immunoglobulin in addition to aerosolised ribavirin could decrease the mortality rate to 50%. 11, 21 Treatment with intravenous ribavirin has been associated with 80% mortality and high rates of haemolysis. 5, 22 The treatment of established RSV infection remains controversial, with moderate improvements of survival rates reported with aerosolised ribavirin and high-titred RSV immunoglobulin. 8, 14 In our hands, a favourable outcome in comparison to the other series was seen despite no specific treatment for RSV pneumonia (Table 5 ).
An interesting finding to emerge from our study is the potential impact of RSV infection on the kinetics of engraftment following stem cell transplantation. Two autografted patients had neutrophil engraftment 40.5 Â 10 9 /l on days 14 and 21 and an allografted patient suffered graft failure. The autgrafted patients had delayed platelet engraftment 425/nl on days 18 and 15 and had reached platelet levels 450/nl on days 21 and 20, respectively. The median time to platelet engraftment 450/nl following autograft was reported by To et al 26 to be 11 days for the patients who received stem cell doses of 1.5-4.9 Â 10 6 /kg. The median time to neutrophil engraftment following autograft was reported to be 11 days for the patients who received stem cell doses of 1.5-4.9 Â 10 6 /kg, with 90% of patients having neutrophil engraftment before day 14 and all patients reaching 0.5 Â 10 9 /l neutrophils by day 18. 26 Furthermore, the autografted patient with multiple myeloma (case no. 8) had neutrophils 4500/ml on day 11 and platelets 450/nl on day 12 following the second transplant without RSV or other viral infections compared to days 20 and 21, respectively, for the first ABSCT with RSV infection (Table 3 ). This outcome is strongly suggestive that the delayed engraftment following the first transplant was due to the RSV infection. Thus, the effect of RSV infection on the neutrophil and platelet engraftment kinetics postautologous stem cell transplantation is a novel clinical observation, which needs further investigation. While the incidence of graft failure following T-celldepleted HLA-matched sibling nonmyeloablative allografts is less than 10%, [27] [28] [29] it is of interest that the allografted patient had transient recovery that commenced at the time of RSV infection, and then shortly thereafter developed graft failure. In addition, the impact of RSV infection on engraftment postallografting, which has been reported previously by McCarthy et al, 14 requires observation and clarification.
There is only a little information available concerning possible mechanisms of how RSV infection may affect engraftment; some publications suggest that an immunomodulatory effect occurs in RSV infection. Sheeran et al 30 examined nasopharyngeal and tracheal aspirates from children with RSV infection for a number of cytokines (MIP-1 alpha, IL-6, IL-8, IL-10). They showed that the levels of these cytokines were elevated in patients compared to controls, but did not comment on circulating levels. Gershwin et al 31 showed that bovine RSV was associated with a T-helper cell type 2 response with increased expression of IL-4 in draining pulmonary lymph nodes. Furthermore, Chang and Braciale 32 suggested that the RSV infection could inhibit the function of effector T cells and accordingly the immunologic memory development in the respiratory tract. These studies suggest that RSV infection could alter cytokine profiles that could impair haematopoietic stem cell engraftment and proliferation. However, studies specifically addressing this have not been published. Further investigations are warranted.
Our findings together with those of McCarthy et al 14 support the delaying of transplantation in patients with RSV infection, and the aggressive implementation of strict infection control measures at the time of community outbreaks. It is also worth noting that the outcome in our series of RSV pneumonia is no different from others who employed RSV-specific antiviral therapy (Table 5 ).
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